The MITOS system predicts long-term survival in amyotrophic lateral sclerosis (Q41052218)

26 September 2017

title

The MITOS system predicts long-term survival in amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

26 September 2017

main subject

0 references

4

Gabriele Mora

1 reference

26 September 2017

3

Adriano Chiò

1 reference

26 September 2017

Irene Tramacere

1

1 reference

26 September 2017

Eleonora Dalla Bella

2

1 reference

26 September 2017

Graziella Filippini

5

1 reference

26 September 2017

Giuseppe Lauria

6

1 reference

26 September 2017

EPOS Trial Study Group

7

1 reference

26 September 2017

language of work or name

English

0 references

publication date

17 April 2015

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

26 September 2017

published in

1 reference

26 September 2017

volume

86

1 reference

26 September 2017

issue

11

1 reference

26 September 2017

page(s)

1180-1185

1 reference

Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Clinical diagnosis and management of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Measuring function in advanced ALS: validation of ALSFRS-EX extension items

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

Learning from failed trials in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-310176

21 January 2018

Identifiers

DOI

10.1136/JNNP-2014-310176

1 reference

26 September 2017

1 reference